Genzyme did not get support from an FDA advisory panel to market pediatric leukemia drug Clolar to adults with acute myeloid leukemia. In a 9-3 vote, the panel advised the company to conduct a randomized trial of Clolar to provide "an evidence-based justification" that the product is more effective than other treatments.

Full Story:

Related Summaries